Pharmanutra (BIT:PHN) Stock Price Cools As Revenue Growth Meets Earnings Drift

Pharmanutra’s stock has been cooling for weeks, with the share price down about 14% over three months and a rich P/E near 36x that asks investors to pay up for the story. The latest quarter has given that premium a fresh stress test. Revenue reached €41.0m and net income hit €6.5m, solid figures that keep the growth narrative alive but come against a backdrop of a share price already trading above a discounted cash flow estimate of €64.01. The tension between strong reported progress and an expensive valuation is now front and centre.

Is Pharmanutra already pricing in years of strong growth, or has the recent pullback begun to create a margin of safety for new investors? Explore the gap between premium multiples and cash flow reality in our valuation analysis for Pharmanutra

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): €41.037m vs. €36.274m (up about 13.1%)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): €6.471m vs. €6.749m (down about 4.1%)
• Basic EPS (Q2 2026 vs. Q2 2025): €0.681848 vs. €0.718634 (down about 5.1%)
• Trailing 12-Month Net Profit Margin (Latest vs. Prior Year): 14.5% vs. 13.8% (margin improved by 0.7 percentage points)

Prefer clear visuals instead of another dense block of Pharmanutra numbers and ratio tables? See the full picture in one place, including how valuation compares with recent earnings progress, through our company report for Pharmanutra.

Pharmanutra earnings and the constructive case

Pharmanutra gives bulls some support. Top line moved to €41.037m against €36.274m, which fits a story of products gaining traction across nutraceutical and medical device channels. Profitability looks resilient, with trailing 12 month net margin at 14.5% compared with 13.8%, important for a business that sells science based formulations rather than pure consumer brands. Revenue expansion alongside a firmer margin suggests the product mix and international reach are not being bought with heavy discounting or runaway costs.

Where the Pharmanutra risk narrative still bites

There is also fuel for skeptics. Net income excluding extra items slipped to €6.471m from €6.749m and basic EPS eased to €0.681848 from €0.718634, which hints at near term earnings pressure even as sales rise. That softening, combined with a share price that has fallen about 14% over 90 days, lines up with concerns that competition, regulation or execution in crowded health markets can squeeze returns, even for a company with proprietary delivery technologies.

Reveal whether Pharmanutra’s mix of solid reported margins and a cooling share price at €78.8 still lines up with what the street expects by checking the consensus price target analysis for Pharmanutra

Stay Ahead Of Your Next Move

Pharmanutra’s mix of a rich P/E and recent share price pullback makes timing matter, so register for free with Simply Wall St and add it to your Watchlist to track price against fair value before committing capital. Once you own it, keep your decisions anchored in data rather than headlines by managing everything through the Portfolio Command Center that highlights only the most important changes to your holdings. For a wider lens on what might shift sentiment next, use the Community to see how other investors are thinking about Pharmanutra and similar stocks. By catching fresh catalysts and emerging risks early, you can stay proactive in your approach to the market.

Seeking Alternatives Beyond Pharmanutra Now

Fresh ideas move first. Breakout stories, early momentum and stocks flying under the radar for now rarely stay quiet for long, so scan these curated lists and act now.

• Spot cash rich businesses before momentum really builds by reviewing the 184 high quality undervalued stocks while the gap between fundamentals and sentiment still offers room to move.
• Track companies quietly powering the AI build out by scanning the 89 AI infrastructure stocks before infrastructure winners are fully caught in the spotlight.
• Target income ideas built on resilience by checking the 161 dividend fortresses while yields remain elevated and attention is still elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com